Providing Space for Life Innovation
Warren Avenue Investors, founded in 2017 by President Matthew McDevitt, is a corporate real estate development and investment company specializing in the life sciences industry.
From start-ups to big corporate companies, Warren Avenue Investors has expertise in high quality properties across the country and internationally.
With over 30 years of experience in commercial life sciences real estate, Matthew McDevitt is an industry expert.
Prior to starting Warren Avenue Investors, Matthew served as one of the Founders and the Executive Vice President for one of the leading providers of real estate in the life sciences industry for over 12 years, BioMed Realty. During his time there, he maximized the shareholder value, growing it from $475 million public offering to an $8 billion sale to Blackstone.
Matthew served as President of McDevitt Real Estate Services, Inc. (MRES). MRES was a full service real estate brokerage firm focusing on the life sciences industry. He also spent 10 years as a commercial real estate broker on the I-270 Corridor, now known as “DNA Alley”.
As Director of Investments, Eli oversees all investment activity for Warren Avenue, including acquisitions, financings, developments, dispositions, and asset management.
Prior to joining Warren Avenue, Eli opened the Philadelphia office of Gazit Horizons, the private North American subsidiary of Gazit Globe (TSE: GZT). With Gazit, Eli sourced and underwrote new acquisition opportunities and managed the operations and redevelopment of a local asset.
Before Gazit, Eli spent several years with Eastdil Secured, a leading investment sales and real estate investment bank. During his time with Eastdil, Eli valued more than $10.6Bn of real estate and worked on over $3Bn of closed equity and debt transactions. Eli transitioned to Eastdil from Federal Realty Investment Trust, where he supported the company’s 102 asset, $13Bn portfolio through underwriting investment opportunities and strategic corporate initiatives. Eli graduated from the University of Miami.
As COO, Ryan applies his experience and knowledge of major players and emerging therapies/technologies in the life sciences space to strategize and implements company initiatives, including tenant analysis, new investment opportunities and business development.
Before Warren Avenue, Ryan held a position with The Discovery Labs, the world’s largest and most advanced single solution cell and gene therapy contract development and manufacturing organization (CDMO). As an investment analyst, Ryan worked to create complex partnership agreements with potential clients.
Before The Discovery Labs, Ryan began his career with BioMed Realty Trust, working within the Leasing and Development department. During his time at BioMed, Ryan supported the company navigate various regulatory, operational, and financial objectives. Ryan graduated from Villanova University.
As VP of Construction & Development, Mark oversees all design and construction activities for projects across the country. He works closely with our investment team developing strategies for emerging markets.
Prior to joining Warren Avenue, Mark held various positions with Turner Construction Company in Philadelphia. During his time there, he built projects ranging from large-scale commercial high rises to pharmaceutical lab spaces. Most recently, as Business Development Manager, Mark successfully launched Turner’s new Delaware office.
Mark brings his understanding of the building process, as well as financial strategies in construction to maximize project value. Mark earned a Bachelor of Science in Civil Engineering from Villanova University and is a licensed Professional Engineer (Structural) in the state of Pennsylvania.
As investment associate, Phil applies his industry experience to support all investment activity for Warren Avenue. This includes the analysis of potential acquisitions and developments as well as financings, dispositions, and asset management.
Prior to joining Warren Avenue, Phil was a financial analyst with Equus Capital Partners. With Equus, Phil participated in the acquisition, disposition, recapitalization, or development of approximately $2.5Bn in transaction volume across multiple product types. He also assisted in the asset management of over 1 million square feet of commercial property.
Prior to Equus, Phil studied at Villanova University where he graduated with a degree in Finance and Real Estate.